A Phase I/II Open-label Multicenter Study of AT7519M Alone and in Combination With Bortezomib in Patients With Previously Treated Multiple Myeloma

Trial Profile

A Phase I/II Open-label Multicenter Study of AT7519M Alone and in Combination With Bortezomib in Patients With Previously Treated Multiple Myeloma

Completed
Phase of Trial: Phase I/II

Latest Information Update: 25 Sep 2016

At a glance

  • Drugs AT 7519 (Primary) ; Bortezomib
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Sponsors Astex Therapeutics
  • Most Recent Events

    • 07 Aug 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 24 Jun 2014 Planned End Date changed from 1 Oct 2013 to 1 Mar 2015 as reported by ClinicalTrials.gov.
    • 24 Jun 2014 Planned primary completion date changed from 1 Jun 2013 to 1 Dec 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top